| US 7,488,832 B2 | ||
| Azolylacylguanidines as β-secretase inhibitors | ||
| Derek Cecil Cole, New City, N.Y. (US); Eric Steven Manas, Lafayette Hill, Pa. (US); Lee Dalton Jennings, Chestnut Ridge, N.Y. (US); Frank Eldridge Lovering, Acton, Mass. (US); Joseph Raymond Stock, Monroe, N.Y. (US); William Jay Moore, Collegeville, Pa. (US); John Watson Ellingboe, Ridgewood, N.J. (US); Jeffrey Scott Condon, Cambridge, Mass. (US); Mohani Nirmala Sukhdeo, Richmond Hill, N.Y. (US); Ping Zhou, Plainsboro, N.J. (US); Junjun Wu, Arlington, Mass. (US); and Koi Michele Morris, Plainsboro, N.J. (US) | ||
| Assigned to Wyeth, Madison, N.J. (US) | ||
| Filed on Feb. 13, 2006, as Appl. No. 11/352,820. | ||
| Claims priority of provisional application 60/652696, filed on Feb. 14, 2005. | ||
| Prior Publication US 2006/0183790 A1, Aug. 17, 2006 | ||
| Int. Cl. C07D 207/325 (2006.01); A61K 31/4025 (2006.01) | ||
| U.S. Cl. 548—560 [514/427] | 8 Claims |
1. A compound having the structure
 X is CH;
Y is CH;
R is H or alkyl;
R3 and R4 are each independently H, alkyl, alkoxy, alkanoyl, alkenyl, cycloalkyl, or aryl;
R7, R8, R9 and R10 are each independently H, halogen, alkyl, haloalkyl, cycloalkyl, aryl, OR11, COR11, CONR12R13, NR12R13, NR14COR15, NR14SO2R15 or NR14CONR16R17;
R11 is H, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, or aryl;
R12, R13, R16 and R17 are each independently H, alkyl, alkoxy, alkenyl, cycloalkyl, or aryl;
R14 is H, alkyl or cycloalkyl; and
R15 is alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl, or, aryl; or
a tautomer thereof, a stereoisomer thereof or a pharmaceutically acceptable salt thereof.
|